Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells

Prof. Franco DOSIO
Dott. Paola MILLA
Prof. Silvia ARPICCO

Aree / Gruppi di ricerca

Partecipanti al progetto

Descrizione del progetto

Members of other units:
Marta Palmieri, Chiara Costanzo (Department of Life and Reproduction Sciences, Biochemistry Section, University of Verona)
Elisa Zoratti (Applied Research on Cancer–Network, University of Verona, Verona, Italy)
Aldo Scarpa (Department of Pathology and Diagnostics, University of Verona, Verona, Italy)

Local funds University of Turin, Italy 
Project Verona Nanomedicine Initiative, Italy 

Pancreatic adenocarcinoma is often diagnosed when metastatic events have occurred. The early spread of circulating cancer cells expressing the CD44 receptor may play a crucial role in this process. This project is based on the cellular delivery ability and both in vitro and in vivo anti-tumoral activity of liposomes conjugated with two different low molecular weight hyaluronic acids (HA 4.8 kDa and HA 12 kDa), the primary ligand of CD44, and containing a lipophilic gemcitabine pro-drug. The liposomes are fully characterized from a technological point of view and through in vitro tests.

- Arpicco S. et al, 2013. European Journal of Pharmaceutics and Biopharmaceutics in press
- Dalla Pozza E. et al, 2013. BBA Biomembranes 1828, 1396–1404

CD44, Hyaluronic acid-conjugated liposomes, Pancreatic cancer, Active targeting

Ultimo aggiornamento: 30/03/2015 15:52
Campusnet Unito
Non cliccare qui!